The Benchmark That Made GPT-Rosalind Famous Measures Bioinformatics. Drug Discovery Is a Different Problem.
GPT-Rosalind scored 0.751 on BixBench — a 0.201-point lead over Gemini 3.1 Pro — and launched with Amgen, Moderna, and Novo Nordisk as partners. Coverage treated this as the opening of AI drug discovery at scale. BixBench measures sequencing data processing, statistical analysis, and genomic interpretation — the computational work biologists do before drug discovery begins. No benchmark measuring actual drug discovery milestones (target identification, lead optimization, ADMET prediction) has been published for GPT-Rosalind. No fully AI-discovered drug has cleared Phase III anywhere. The four largest pharma companies by revenue — Pfizer, Roche, J&J, Merck — are not launch partners. And nobody disclosed what Amgen, Moderna, and Novo Nordisk actually agreed to.
GPT-5.4 found a chemistry improvement. The automated lab that made it possible got buried in the headline.
OpenAI and Molecule.one ran 10,080 reactions and found a real yield improvement for Chan-Lam coupling — a 52% relative gain, experimentally validated. The result is genuinely interesting and the quantitative numbers hold. Three caveats are absent from every piece of coverage: the preprint isn't peer-reviewed, the validation was done by the authors themselves, and the raw data won't be released. Also missing: the irreplaceable component in this experiment wasn't GPT-5.4 — it was Molecule.one's Maria Lab automated chemistry platform. A pharma company with an API key and no automated lab cannot replicate this result.
Mayo Clinic Says It Owns the AI Model It's Building With Microsoft. The Contract Terms Say Something Else — But We Don't Know What.
At Microsoft Build 2026 on June 2, Mustafa Suleiman and Mayo Clinic CEO Dr. Farrugia announced a frontier AI model trained on 54 million de-identified patient records — owned by Mayo, distributed globally via Azure Foundry. The headline is 'Mayo owns the model.' The actual IP terms — does Mayo have unconditional weight access outside Azure, does Microsoft hold any license for MAI development, is the distribution Azure-exclusive — are not publicly disclosed. The model does not exist yet; this is an announcement of intent to build. No coverage has asked the two questions that determine whether 'Mayo owns it' is an IP fact or marketing language. No coverage has asked the FDA whether a hospital-owned frontier AI model distributed as a global API is a device.
AI Drug Discovery Startup Chai Raises $130M at $1.3B Valuation, Lands Eli Lilly Deal
Chai Discovery, an AI biotech startup founded by former OpenAI and Facebook researchers, has closed a $130M Series B at a $1.3B valuation and announced a partnership with Eli Lilly. The company builds custom protein-language models to accelerate antibody design, representing a major bet on AI-driven drug development.